Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla.
J Cancer Res Ther. 2024 Jan 1;20(1):363-368. doi: 10.4103/jcrt.jcrt_677_22. Epub 2023 Apr 5.
This study aimed to analyze the survivals and clinicopathological features of epithelial ovarian cancer (EOC) in younger age patients and to determine the impact of age on survival.
EOC patients aged ≤40 years were matched to patients aged >40 years at a 1:4 ratio. Disease-specific survival (DSS), progression-free survival (PFS), and clinicopathological and treatment features were compared between patients aged ≤40 and >40 years.
A total of 763 EOC patients were reviewed. During a median follow-up period of 41 (range, 1-195) months, EOC patients aged ≤40 and >40 years did not show any statistically significant difference in median DSS (120 versusversus 84.7 months; hazard ratio, 0.78; 95% confidence interval, 0.58, 1.06); however, the median PFS was better in patients aged ≤40 years (median PFS not reached versusversus 41 months; HR, 0.65; 95% CI, 0.5, 0.85). Age ≤40 years was an independent favorable prognostic factor for DSS at 3 years after diagnosis. In contrast, younger age was an independent poor prognostic factor prior to this time point. EOC patients aged ≤40 years exhibited a significantly higher rate of early-stage disease, a higher proportion of mucinous subtype, and lower cancer antigen-125 level.
Overall, EOC patients in the younger age group were associated with more favorable prognostic factors and showed better PFS, but not DSS, than those in the older age group. Younger age was identified as an unfavorable prognostic factor within 3 years of diagnosis and became a favorable prognostic factor after 3 years.
本研究旨在分析年轻上皮性卵巢癌(EOC)患者的生存率和临床病理特征,并确定年龄对生存率的影响。
将年龄≤40 岁的 EOC 患者与年龄>40 岁的患者以 1:4 的比例进行匹配。比较年龄≤40 岁和>40 岁患者的疾病特异性生存率(DSS)、无进展生存率(PFS)以及临床病理和治疗特征。
共回顾了 763 例 EOC 患者。在中位随访时间为 41(范围 1-195)个月期间,年龄≤40 岁和>40 岁的 EOC 患者在中位 DSS 方面无显著差异(120 与 84.7 个月;风险比,0.78;95%置信区间,0.58,1.06);然而,年龄≤40 岁的患者中位 PFS 更好(中位 PFS 未达到与 41 个月;HR,0.65;95%CI,0.5,0.85)。年龄≤40 岁是诊断后 3 年 DSS 的独立有利预后因素。相比之下,在此之前,年龄较小是独立的不良预后因素。年龄≤40 岁的 EOC 患者表现出更高的早期疾病发生率、更高的黏液性亚型比例和更低的癌症抗原 125 水平。
总体而言,年轻组 EOC 患者具有更有利的预后因素,与年龄较大组相比,PFS 更好,但 DSS 无差异。年龄较小被确定为诊断后 3 年内的不利预后因素,3 年后成为有利预后因素。